Gut macrobiotic and its metabolic pathways modulate cardiovascular disease

Area of Science:

• Microbiology
• Cardiovascular Science
• Metabolomics

Background:

• The human gut harbors trillions of microorganisms crucial for health and homeostasis.
• Gut microbiota disruption (dysbiosis) is linked to metabolic impairment and cardiovascular disease (CVD).
• Microbial metabolites significantly contribute to the pathogenesis of cardiovascular conditions.

Purpose of the Study:

• To review the impact of gut microbiota and their metabolites on cardiovascular health.
• To explore novel therapeutic strategies targeting the gut microbiome for CVD prevention and treatment.

Main Methods:

• Literature review of recent advances in gut microbiota research related to cardiovascular health.
• Analysis of the role of specific microbial metabolites (SCFAs, TMAO, BAs, LPS) in CVD.
• Evaluation of intervention strategies like probiotics and fecal transplantation.

Main Results:

• Gut microbiota metabolites such as SCFAs, TMAO, BAs, and LPS influence hypertension and atherosclerosis.
• These metabolites affect cardiovascular function via altered microbiota composition and signaling pathways.
• Targeting gut microbiota offers a promising approach for cardiovascular health.

Conclusions:

• Gut microbiota and their metabolites are key players in cardiovascular health and disease.
• Microbiome-targeted therapies, including probiotics and fecal transplantation, show potential for CVD management.
• Harnessing microbial metabolites presents a novel therapeutic avenue for cardiovascular conditions.